CorMedix

CRMD

Market cap $856M

Overview Fund Activity

11.47 USD

-0.12

1.04%

At close Updated Sep 17, 11:58 AM EDT

1 day

-1.04%

5 days

-10.39%

1 month

-12.44%

3 months

-17.72%

6 months

9.55%

Year to date

39.54%

1 year

59.08%

5 years

143.52%

10 years

-24.04%

About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Employees: 82

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

257% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 14

187% more capital invested

Capital invested by funds: $146M [Q1] → $421M (+$274M) [Q2]

85% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 34

55% more call options, than puts

Call options by funds: $13M | Put options by funds: $8.42M

25% more funds holding

Funds holding: 136 [Q1] → 170 (+34) [Q2]

13.93% more ownership

Funds ownership: 36.42% [Q1] → 50.35% (+13.93%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

48% upside

Avg. target

$19

66% upside

High target

$22

92% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Jason N. Butler	$22	Market Outperform Reiterated	9 Sep 2025
HC Wainwright & Co. Brandon Folkes	$17	Buy Maintained	8 Aug 2025
Needham Serge Belanger	$20	Buy Maintained	24 Jun 2025
RBC Capital Leonid Timashev	$17	Outperform Reiterated	20 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about CRMD published over the past 30 days

Zacks Investment Research

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?

CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?

CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

CorMedix Inc. (NASDAQ:CRMD ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Joseph Todisco - CEO & Director Conference Call Participants Ross Cohen Presentation Ross Cohen Okay. So thank you all for joining.

CorMedix Inc. (CRMD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zacks Investment Research

CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one additional tranche upon the achievement of the primary endpoint in the NEPHRO clinical study The completion of this financing is expected to provide the company with sufficient capital through the planned approval of a Niyad PMA in the second half of 2026 SAN MATEO, Calif. , Sept. 8, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into securities purchase agreements with CorMedix Inc. and certain institutional investors for the sale and issuance of shares of common stock and pre-funded warrants in lieu of shares to purchase common stock in a private placement for total potential proceeds of up to $29 million.

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

CorMedix Announces Strategic Minority Investment in Talphera

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera's concurrently announced private placement financing.

CorMedix Announces Strategic Minority Investment in Talphera

Zacks Investment Research

Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet

The mean of analysts' price targets for CorMedix (CRMD) points to a 32% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet

Zacks Investment Research

Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?

CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.

Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

- Transformational deal for CorMedix that expands and diversifies company's commercial product portfolio, with seven innovative drug products and a pipeline expansion indication with near-term revenue growth potential -

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

CorMedix to Participate in Upcoming Investor Conferences

BERKELEY HEIGHTS, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be presenting and participating in investor meetings at upcoming investor conferences taking place in September.

CorMedix to Participate in Upcoming Investor Conferences

CorMedix: The Undervalued Breakthrough

CorMedix has achieved GAAP profitability after years of losses, with the market yet to fully price in this turnaround. Shares trade at a moderate 17x forward P/E, but with a projected 8x forward P/E, I see further upside potential. DefenCath's FDA approval and successful commercialization underpin CorMedix's financial strength and independence from larger biotech partners.

CorMedix: The Undervalued Breakthrough

See News Rankings

Charts implemented using Lightweight Charts™